Concepts (62)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epoprostenol | 2 | 2019 | 71 | 1.300 |
Why?
|
| Phenylephrine | 1 | 2020 | 61 | 0.750 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 71 | 0.730 |
Why?
|
| Shock, Septic | 1 | 2020 | 101 | 0.720 |
Why?
|
| Norepinephrine | 1 | 2020 | 276 | 0.710 |
Why?
|
| Vasodilator Agents | 1 | 2019 | 138 | 0.650 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 37 | 0.600 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 450 | 0.460 |
Why?
|
| Administration, Inhalation | 2 | 2019 | 187 | 0.310 |
Why?
|
| Retrospective Studies | 4 | 2021 | 7277 | 0.240 |
Why?
|
| Thromboembolism | 1 | 2021 | 91 | 0.190 |
Why?
|
| APACHE | 1 | 2020 | 41 | 0.190 |
Why?
|
| Heart Failure | 2 | 2021 | 1180 | 0.190 |
Why?
|
| Organ Dysfunction Scores | 1 | 2020 | 13 | 0.190 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 89 | 0.180 |
Why?
|
| Propensity Score | 1 | 2020 | 117 | 0.180 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 215 | 0.180 |
Why?
|
| Thrombosis | 1 | 2021 | 218 | 0.180 |
Why?
|
| Pharmaceutic Aids | 1 | 2019 | 7 | 0.180 |
Why?
|
| Drug Compounding | 1 | 2019 | 34 | 0.170 |
Why?
|
| Hypotension | 1 | 2019 | 74 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 122 | 0.160 |
Why?
|
| Heart-Assist Devices | 1 | 2021 | 221 | 0.160 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 7 | 0.160 |
Why?
|
| Cardiology Service, Hospital | 1 | 2018 | 11 | 0.160 |
Why?
|
| Drug Costs | 1 | 2018 | 87 | 0.150 |
Why?
|
| Middle Aged | 3 | 2020 | 21147 | 0.150 |
Why?
|
| Hypoxia | 1 | 2018 | 169 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 190 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2018 | 344 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 232 | 0.130 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2011 | 28 | 0.120 |
Why?
|
| Female | 3 | 2020 | 38074 | 0.110 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2011 | 9 | 0.100 |
Why?
|
| Lipid Bilayers | 1 | 2011 | 24 | 0.100 |
Why?
|
| Torpedo | 1 | 2011 | 2 | 0.100 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2011 | 8 | 0.100 |
Why?
|
| Fish Proteins | 1 | 2011 | 20 | 0.100 |
Why?
|
| Humans | 5 | 2021 | 68618 | 0.090 |
Why?
|
| Male | 2 | 2020 | 37321 | 0.070 |
Why?
|
| Aged | 1 | 2018 | 14862 | 0.050 |
Why?
|
| Adult | 1 | 2019 | 21403 | 0.050 |
Why?
|
| Protein Structure, Secondary | 2 | 2011 | 136 | 0.050 |
Why?
|
| Aspirin | 1 | 2021 | 295 | 0.040 |
Why?
|
| Phosphatidylglycerols | 1 | 2011 | 8 | 0.030 |
Why?
|
| Phosphatidylcholines | 1 | 2011 | 38 | 0.030 |
Why?
|
| Micelles | 1 | 2011 | 43 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 45 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2011 | 60 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2011 | 99 | 0.020 |
Why?
|
| Microinjections | 1 | 2011 | 130 | 0.020 |
Why?
|
| Oocytes | 1 | 2011 | 57 | 0.020 |
Why?
|
| Protein Stability | 1 | 2011 | 90 | 0.020 |
Why?
|
| Spin Labels | 1 | 2011 | 27 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 204 | 0.020 |
Why?
|
| Liposomes | 1 | 2011 | 107 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2011 | 525 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 742 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1083 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1447 | 0.020 |
Why?
|
| Animals | 2 | 2011 | 20881 | 0.010 |
Why?
|